Sara Bonstein Sells 1,066 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) CFO Sara Bonstein sold 1,066 shares of Insmed stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the transaction, the chief financial officer now directly owns 118,863 shares of the company’s stock, valued at approximately $7,573,950.36. This represents a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Tuesday, January 7th, Sara Bonstein sold 3,470 shares of Insmed stock. The shares were sold at an average price of $65.70, for a total value of $227,979.00.

Insmed Price Performance

INSM opened at $65.25 on Friday. Insmed Incorporated has a 52-week low of $21.92 and a 52-week high of $80.53. The company has a 50 day moving average of $71.23 and a two-hundred day moving average of $72.44. The company has a market cap of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analysts’ expectations of $93.36 million. The business’s quarterly revenue was up 18.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.10) earnings per share. On average, analysts expect that Insmed Incorporated will post -5.44 earnings per share for the current year.

Analyst Ratings Changes

Several research firms have weighed in on INSM. Bank of America raised their target price on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, JPMorgan Chase & Co. boosted their price target on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $83.67.

Hedge Funds Weigh In On Insmed

A number of institutional investors have recently added to or reduced their stakes in the company. V Square Quantitative Management LLC acquired a new stake in shares of Insmed during the third quarter valued at about $30,000. GAMMA Investing LLC boosted its holdings in Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares in the last quarter. Blue Trust Inc. increased its holdings in Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 1,879 shares during the last quarter. Finally, JCIC Asset Management Inc. acquired a new position in shares of Insmed in the 3rd quarter valued at approximately $133,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.